ADC Evidence and Overall Survival Considerations

In this podcast, experts Christine M. Lovly, MD, PhD, FASCO; Lyudmila Bazhenova, MD; Hossein Borghaei, DO, MS; and Xiuning Le, MD, PhD, discuss how to sequence systemic therapy based on the molecular profile of non–small cell lung cancer that has progressed on a first-line EGFR-directed tyrosine kinase inhibitor, including discussion on the use of bispecific antibodies in this setting.